



KOMABIOTECH TO DISTRIBUTE ANTEO'S AMG™ RANGE IN SOUTH KOREA

For Immediate Release:

October 19, 2015

Highlights:

- **Non-exclusive distribution agreement signed with KomaBiotech to drive the Anteo Mix&Go (AMG™) branded products into South Korea**
- **Under the agreement, Koma will sell and market AMG and provide ongoing support to customers**
- **Koma is a leading Seoul-based supplier to the life sciences industry with a long operating history**

October 19 2015 – Anteo Diagnostics (ASX: ADO) (Anteo) is pleased to announce that it has entered into a non-exclusive distribution agreement with KomaBiotech (Koma), who will market, distribute and support the Anteo Mix&Go (AMG™) products in South Korea. AMG™ is Anteo's core nanogluce product range and is undergoing early stage commercialisation. The agreement with Koma is seen as a further strategic step in developing a strong sales channel into South Korea.

Koma is a Korean manufacturer and supplier of reagents and tools for life science research, and has been operating in the Korean market since 1994. Koma is a distributor of Luminex in the South Korean region, and this agreement is expected to provide Luminex customers with easier access to the AMG™ Activation Kit for Multiplex Microspheres, together with the 200nm and 1um Coupling Kit AMG™ products.

The life sciences industry in South Korea is substantial and growing due to the health and economic challenges which accompany the region's rapidly aging population. It has a population of over 50 million people.

The AMG™ range of products enable life science researchers to utilise the Mix&Go universal surface across a variety of assay formats, increasing sensitivity, reducing development time, enabling labs to deliver outcomes to market faster and more consistently.

Anteo is commercialising its AMG™ nanogluce technology and is implementing a multifaceted sales model, comprising direct AMG™ product sales via distributors, co-development of novel Mix&Go enabled products with partners and the licensing of Mix&Go for use in partner products.

Anteo's CEO, Dr. Geoff Cumming, commented: "We are pleased to be able to work with Koma, an established market leader in South Korea, which has a long and respected history of servicing this region."

"Our AMG™ product range is ideally suited to the growing Korean market and this agreement adds to the work we've been doing to extend our distribution network in other regions in 2015."

"Having a partner like Koma in South Korea which is expert in sales, marketing and the provision of quality customer support is important for Anteo. Since the AMG range is relatively new, having representatives on the ground who can ensure customers are getting the most from the products is the greatest way to deliver best adoption practices. Under this agreement, Koma will ensure that support, training and service is delivered appropriately," finished Dr Cumming.

Ms KJ Sohn, General Manager for Koma commented, "Anteo products are excellent tools for researchers who are developing multiplexing kits, due to their ability to increase sensitivity and consistency when coupling a broad range of molecules."

"Koma has been doing Luminex business since 2005, so we are very excited to be able to distribute the Anteo products in the Korean market as a new solution for customers. We expect the combination of Anteo's cutting edge technology and Koma's sales and marketing experience to lead to a successful launch of AMG in the Korean market."



During the course of 2015, Anteo has successfully entered into distribution agreements with major life science companies including US based giant Sigma Aldrich, and Veritas – a distributor in Japan. The Company is currently finalising the previously announced acquisition of Belgian specialist diagnostics company, DIAsource ImmunoAssays SA, under which it will further significantly extend global distribution reach for its AMG™ product range. The appointment of Koma as a distributor for the AMG™ range represents another positive step, this time into the attractive South Korean market.

For further information, see our website (www.anteodx.com) or contact the persons outlined below.

Company	Media and Investor Relations
Dr. Geoff Cumming, Chief Executive Officer T: + 61 7 3219 0085	Jane Lowe, IR Department E: jane.lowe@irdepartment.com.au T: + 61 411 117 774
Richard Martin, Chief Financial Officer T: + 61 7 417 229 810	

About Anteo Diagnostics

Anteo Diagnostics (ASX: ADO) is a global medical technology company, developing and commercialising products for sale into the life sciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets.

The Anteo group owns a patented nanoglue technology, which is used by healthcare customers as an addition to their existing tests, to consistently enable laboratory test results that can either be delivered faster, cheaper, or with greater specificity or sensitivity than incumbent tests.

This nanoglue technology, called Mix&Go for healthcare markets, is starting to gain traction with the Company's target markets, due to its ability to revolutionise the way scientists work.

While Anteo is largely focused on the healthcare markets, the nanoglue technology also has potential for use in other areas, such as batteries. Early stage research is being conducted into the viability of this battery product.

For more information, please visit www.anteodx.com

About Koma Biotech

Based in Seoul, Korea, Koma Biotech manufactures and provides reagents and tools for life science research. The comprehensive product lines support applications in the study of all major life science research areas, including molecular biology, immunology, cell biology, proteomics and genomics research. Key products include protein electrophoresis systems and pre-cast gels, PCR amplification reagents, Transfection reagents, Direct PCR, nucleic acid purification kits and ELISA kits for cytokines and immunoglobulins.

Koma Biotech improves productivity for customers and help them by providing a broad spectrum of reagents, kits, and technologies for life science research.

For more information, please visit www.komabiotech.co.kr